Micafungin
ApprovedTerminated 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Candidemia
Conditions
Candidemia, Candidiasis
Trial Timeline
Sep 26, 2013 → Aug 28, 2015
NCT ID
NCT01982071About Micafungin
Micafungin is a approved stage product being developed by Astellas Pharma for Candidemia. The current trial status is terminated. This product is registered under clinical trial identifier NCT01982071. Target conditions include Candidemia, Candidiasis.
What happened to similar drugs?
3 of 7 similar drugs in Candidemia were approved
Approved (3) Terminated (1) Active (3)
🔄Fosmanogepix + Fosmanogepix + Caspofungin + Fluconazole + Placebo + Placebo + Placebo + PlaceboBasilea PharmaceuticaPhase 3
Hype Score Breakdown
Clinical
20
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (15)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03174457 | Pre-clinical | Completed |
| NCT03102658 | Approved | Completed |
| NCT02440178 | Phase 2 | Completed |
| NCT03421002 | Phase 2 | Completed |
| NCT02678598 | Pre-clinical | Completed |
| NCT02127788 | Pre-clinical | Completed |
| NCT02646800 | Approved | Terminated |
| NCT02646774 | Approved | Terminated |
| NCT02057289 | Phase 1 | Terminated |
| NCT01982071 | Approved | Terminated |
| NCT01135589 | Approved | UNKNOWN |
| NCT00606268 | Phase 1 | Completed |
| NCT00608335 | Phase 1 | Completed |
| NCT00818584 | Phase 1 | Completed |
| NCT00842504 | Phase 1 | Completed |
Competing Products
9 competing products in Candidemia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| micafungin + Micafungin + Caspofungin | Astellas Pharma | Approved | 43 |
| AmBisome | Gilead Sciences | Approved | 43 |
| Anidulafungin/Fluconazole | Pfizer | Phase 3 | 32 |
| Anidulafungin + Voriconazole | Pfizer | Approved | 43 |
| Anidulafungin + Fluconazole | Pfizer | Phase 3 | 40 |
| Anidulafungin | Pfizer | Phase 3 | 40 |
| Fosmanogepix + Fosmanogepix + Caspofungin + Fluconazole + Placebo + Placebo + Placebo + Placebo | Basilea Pharmaceutica | Phase 3 | 41 |
| APX001 | Basilea Pharmaceutica | Phase 2 | 29 |
| APX001 | Basilea Pharmaceutica | Phase 2 | 29 |